NervGen Pharma (NASDAQ:NGEN) Given Average Rating of “Moderate Buy” by Analysts

Shares of NervGen Pharma (NASDAQ:NGEN) have received an average recommendation of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $18.00.

NGEN has been the subject of several recent research reports. HC Wainwright upgraded NervGen Pharma to a “strong-buy” rating in a research report on Tuesday, April 28th. Weiss Ratings began coverage on NervGen Pharma in a report on Friday, April 24th. They set a “sell (d-)” rating for the company. Zacks Research upgraded NervGen Pharma to a “hold” rating in a report on Wednesday, April 29th. TD Cowen began coverage on NervGen Pharma in a report on Thursday. They set a “buy” rating for the company. Finally, Wall Street Zen upgraded NervGen Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 29th.

NervGen Pharma Trading Down 4.4%

Shares of NGEN stock opened at $1.73 on Thursday. NervGen Pharma has a fifty-two week low of $1.70 and a fifty-two week high of $6.30.

NervGen Pharma (NASDAQ:NGEN) last announced its quarterly earnings data on Friday, May 15th. The company reported $999.00 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $999.07.

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.